Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Criteria for exclusion reported during the enrollment period

From: Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study

Declined to participate (n = 26) Secondary arterial hypertension (n = 5)
Previous allergic reaction to ACEIs (n = 3) Previous allergic reaction to ARBs (n = 2)
Active disease in other organs (n = 6) Previous gastrointestinal surgery (n = 1)
Diseases causing malabsorption (n = 1) Recent (1 year) ischemic episodes (n = 9)
History of ventricular arrhythmias (n = 2) History of cardiac insufficiency (n = 8)
Current prescription with diuretics (n = 9) Current prescription with potassium (n = 4)
Current prescription with B-blockers (n = 7) Current prescription with NSAIDs (n = 3)
  1. ACEIs: Angiotensin-converting enzyme inhibitors, ARBs: Angiotensin receptor blockers, NSAIDs: nonsteroidal anti-inflammatory drugs, B-blockers: Beta-blockers.